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In part II of this review, we describe the epidemiology and clinical consequences of vascular disease in patients with diabetes, and discuss the ef-
ficacy of risk factor modification and antiplatelet treatment. Specifically, evidence-based cardiovascular therapies are discussed through novel
clinical insights on management of hyperglycaemia, hypertension, dyslipidaemia as well as platelet dysfunction. Recent trends in the incidence
and outcomes of vascular disease in diabetes suggest that timely and effective implementation of therapies is making a favourable impact.
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Introduction
Diabetes and vascular disease are intimately linked and share patho-
physiological features as examined in Part I of this review. In this
section, we review the epidemiology and clinical consequences of
vascular disease in patients with diabetes, and discuss the efficacy
of risk factor modification and antiplatelet treatment. Since the
reviews published on this topic by the authors previously,1,2 contem-
porary trends in the incidence and outcomes of vascular disease in
diabetes suggest that timely and effective implementation of therap-
ies is making a favourable impact.
Epidemiology of diabetes and
atherosclerosis
In the late 1990’s and early 2000s, there was a marked increase in the
rate of obesity and diabetes across the globe.3 These changes were
observed and reported in the United States,4 Europe,5,6 Africa,7
China,8,9 and India.10 In 1997, Amos et al.11 predicted the worldwide
burden of diabetes would increase from 124 to 221 million people in
2010, with particular gains in Asia and Africa. In retrospect, these pre-
dictions now seem optimistic as the World Health Organization esti-
mates a current worldwide prevalence of 346 million patients with
diabetes12 (Figure 1). Evidence suggests that the rates of obesity
and diabetes may be leveling off in Europe and the United States
but continue to increase in Asia and Africa, making clear the global
nature of the problem.13–16
Recently, investigators have identified subsets of patients with dia-
betes at the highest risk. In a meta-analysis of 29 clinical trials that
included at least 1000 patients with diabetes, two factors were
noted to identify a higher risk cohort within the diabetes population:
the presence of cardiovascular disease and the presence of protein-
uria.17 Cardiovascular disease increased the rate of all-cause death
nearly three-fold and the rate of cardiovascular death nearly five-fold
in subjects with diabetes. These results are in concordance with
another systematic review of large trials in patients with diabetes,
demonstrating the association of renal disease, measured either by
the function or presence of proteinuria with increased mortality.18
Coronary heart disease
The impact of diabetes on atherosclerosis is best documented in
terms of its association with coronary heart disease and cardiovascu-
lar events. Several studies make clear that patients with diabetes are
several-fold more likely to develop myocardial infarction than
matched subjects without diabetes. In a seminal Finnish study, the
presence of diabetes increased the 7-year risk of myocardial infarc-
tion and death in older subjects.19 It was from this study that the
concept of diabetes as a coronary heart disease risk-equivalent
began, and culminated in its coronation as a high-risk cardiovascular
state requiring secondary prevention level care as recommended in
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the Adult Treatment Panel III of the National Cholesterol Education
Program several years later.20 More recent evidence, however, sug-
gests that although diabetes increases the risk of coronary heart
disease, it may not reach risk-equivalence for adverse cardiovascular
outcomes. In aDanishpopulationstudy, the riskof adversecardiovas-
cular events (composite of myocardial infarction, stroke, or cardio-
vascular death) was lower in both men and women with diabetes
and no prior myocardial infarction than in non-diabetic men and
women with prior myocardial infarction.21 Bulugahapitiya et al.22
reviewed 13 studies, comprising 45 108 patients with follow-up
ranging from 5 to 25 years. In this meta-analysis, patients with dia-
betes had a 43% lower risk of developing coronary heart disease
events than patients without diabetes but with previous myocardial in-
farction. The lesser cardiovascular risk found in the meta-analysis as
compared with previous studies, may be attributed, in part, to the
lower glucose threshold used for the diagnosis of diabetes, such that
a relatively less sick population now carried the same diagnosis.23
Nonetheless, patients with diabetes still carry a significantly increased
risk of coronary heart disease compared with patients without it.
Despite the lack of risk equivalency, the relevance of diabetes to
atherosclerosis has been made clear through another observation:
a majority of patients with coronary heart disease have insulin resist-
ance or frank diabetes. Norhammar et al.24 studied 181 consecutive
patients admitted to coronary care units with acute myocardial in-
farction and glucose of,11.1 mmol/L. Despite specifically excluding
subjects with knowndiabetes, oral glucose tolerance testing (OGTT)
at discharge showed that 35% of subjects had impaired glucose toler-
ance and 31% had previously undiagnosed diabetes. These results
were confirmed in the much larger Euro Heart Survey performed
in 110 medical centres in 25 nations.25 In Euro Heart, 4961 subjects
with coronary artery disease but no known diabetes were enrolled,
and a majority of these patients were subsequently found to have dia-
betes, impaired glucose tolerance, or impaired fasting glucose
(Figure 2). Using OGTT, 18% of subjects were newly diagnosed
with diabetes, 32% had impaired glucose tolerance, and 5% had
impaired fasting glucose. The results have been replicated in
non-European populations as well.26
Even in recent clinical trials, adverse events associated with symp-
tomatic coronary heart disease are higher in patients with diabetes
Figure 1 Worldwide prevalence of diabetes mellitus in persons aged 20–79 years. The prevalence of diabetes is high. Colours indicate percent
prevalence in respective nations. Source: Diabetes Atlas 5, International Diabetes Federation. Permission granted by the International Diabetes Fed-
eration.
Figure 2 Insulin resistance in patients referred for cardiac evalu-
ation. Results of oral glucose tolerance testing in a survey of 4196
non-diabetic patients referred to a cardiologist for coronary
artery disease (2107 for an acute cardiac problem and 2854 for
an elective evaluation) from 110 centres in 25 countries. More
than half of all patients with coronary artery disease, when present-
ing with an acute or chronic cardiac condition, have evidence of
insulin resistance, even after excluding patients with known dia-
betes. IGT, Impaired glucose tolerance. Adapted from Bartnik
et al.25
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than in patients without it. In the Metabolic Efficiency With Ranola-
zine for Less Ischemia in Non-ST-Elevation Acute Coronary
Syndromes6-TIMI 36 trial of 6560 patients with non-ST-segment ele-
vation myocardial infarction, subjects with diabetes had higher rates
of the composite endpoint of cardiovascular death, myocardial in-
farction, or recurrent ischaemia.27 In the Trial to Assess Improve-
ment in Therapeutic Outcomes by Optimizing Platelet Inhibition
With Prasugrel-Thrombolysis in Myocardial Infarction 38 (TRITON-
TIMI 38),28 of 13 608 subjects with acute coronary syndromes, prasu-
grel lowered adverse event rates, but patients with diabetes still had
higher levels of myocardial infarction, cardiovascular death, and stent
thrombosis than patients without diabetes. In a Danish study of 3655
consecutive patients with ST-segment elevation myocardial infarc-
tion treated with percutaneous coronary intervention, diabetes
was associated with a more than two-fold increase in the rate of myo-
cardial infarction and all-cause mortality over 3 years of follow-up.29
Diabetes worsens outcomes after coronary revascularization as well,
with higher rates of stent thrombosis, both early and late,30–33 and
mortality after coronary artery bypass grafting.34,35 In a prospective
cohort study of more than 36 000 patients, those with diabetes had
a 25% excess mortality compared with those without.36 Complica-
tions of diabetes, like renal failure, further increase the rate of
adverse events when compared with diabetes alone.
Over the last decade, both the recognition by the medical com-
munity of the impact of diabetes on atherosclerosis and the efforts
to modify the increased risk have improved.37 In Sweden, risk factor
modification has improved in this cohort even years after diagnosis.
Fha¨rm et al.38 evaluated 19 382 diabetic patients in cross-sectional
surveys from 2003 to 2008 as well as a subgroup of 4293 patients
followed individually from the year of diagnosis to a mean 2.6 years of
follow-up. They found that treatment goals for HbA1c, blood pres-
sure, total cholesterol, and LDL cholesterol improved over the 5
years of cross-sectional analysis and were achieved ultimately in
78.4, 65.5, 55.6, and 61.0% of patients, respectively. The results
were similar in the National Health and Nutrition Surveys
(NHANES) over the 1998–2008 time period. Significant improve-
ments were seen in the control of HbA1c (37.0–55.2%), blood pres-
sure (35.2–51.0%), and low-density lipoprotein-cholesterol (LDL-C;
32.5–52.9%).39
As a result of better available medical therapy and more pervasive
use of these therapies, the risk of myocardial infarction in the patients
with diabetes has diminished. Using the United Kingdom Prospective
Diabetes Study risk calculator, the estimated 10-year risk for coron-
ary heart disease decreased from 21.1% in 1999–2000 to 16.4% in
2007–2008.40 The impact of therapy may even extend to mortality.
Gregg et al.41 compared 3-year death rates of four consecutive na-
tionally representative samples from the National Health Interview
Surveys linked to National Death Index (1997–1998, 1999–2000,
2001–2002, and 2003–2004) of US adults aged 18 years and
older. Among the individuals with diabetes, the cardiovascular
death rate declined by 40% and all-cause mortality declined by 23%
when comparing the earliest and latest time periods. Reductions in
mortality, however, were not noted in the Framingham population
when pre-1976 and pre-2001 time periods were compared.42 The
difference in findings may reflect the routine incorporation of
statins into therapy of patients with diabetes after the Heart Protec-
tion Study43 was released in 2002.
Stroke
Diabetes also contributes significantly and increasingly to the burden
of stroke.44,45 In the INTERSTROKE case–control study, performed
in 22 nations, diabetes increased the rate of stroke by 35% when com-
paring the top to the bottom tertile, and was associated with 5% of
the population attributable risk for stroke.46 The Emerging Risk
Factors Collaboration analysed 698 782 people from 102 prospect-
ive studies, finding that diabetes was associated with a 2.27-fold in-
crease in the risk of ischaemic stroke and 56% excess rate of
haemorrhagic stroke.47 Following a stroke, diabetes attenuates cog-
nitive recovery,48 limits functional outcome,49 and increases mortal-
ity.50 Diabetes increases the riskof recurrent strokeas well. In the Life
Long After Cerebral ischemia (LiLAC) cohort study, diabetes
increased the risk of recurrent fatal and non-fatal stroke more than
two-fold.51
Identification and implementation of effective therapies have
begun to reduce the risk of stroke in diabetes. In Finland, both the
population attributable risk of stroke and prognosis after stroke are
decreasing over time in patients with diabetes.52,53 Improvements
in control of hypertension, dyslipidaemia, and treatment of diabetes
have been demonstrated as well in the NHANES survey,54 and are
likely contributing to more favourable outcomes and a lower rate
of recurrence. Data showing better outcome of stroke overall are
not uniform, however.45,55 For example, Harmsen et al.55 reported
a tripling in the incidence of diabetes in patients with stroke, but no
change in stroke incidence and mortality in Gothenburg, Sweden
between 1987 and 2006.
Peripheral artery disease
Increasing rates of diabetes also have implications for the prevalence
and prognosis of peripheral artery disease. In the German Epidemio-
logical Trial on Ankle Brachial Index (GETABI), which screened 6880
consecutive primary care patients aged 65 years or older, 1743
(25.3%) had diabetes.56 In the entire cohort, the prevalence of
PAD, defined by an abnormal ankle–brachial index, was 19.8% for
men and 16.8% for women.57 Compared with patients without dia-
betes, patients with diabetes had a higher prevalence of PAD, (26.3
vs. 15.3%) and intermittent claudication (5.1 vs. 2.1%).56 The rate
of PAD in patients with diabetes also increases with age, as it does
in non-diabetic persons. In a multicentre cross-sectional study of
patients older than 70 years with diabetes, 71% had PAD when
detected by abnormal ankle–brachial index.58
Diabetes increases the incidence of critical limb ischaemia (CLI)
four-fold in patients with peripheral artery disease (Figure 3).59 More-
over, in diabetic patients with CLI, 50% will develop CLI in the contra-
lateral limb within 5 years.60 Also, results of revascularization,
whether percutaneous or surgical, are worse in patients with dia-
betes, and there is a higher rate of cardiovascular morbidity asso-
ciated with the procedure.61
It is not established whether aggressive risk factor modification
decreases the risk of PAD in patients with type 2 diabetes. In 1533
patients with type 2 diabetes randomized to intensive risk factor
control or standard therapy, there was no difference after 6 years
in the prevalence of peripheral artery disease.62 Despite this, most
data suggest that the rate of complications, and specifically diabetes-
related amputation, declined over the last decade.63– 65 Using the
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National Hospital Discharge Survey and National Health Interview
Survey Data, Li et al.66 showed a decrease in the age-adjusted non-
traumatic lower extremity amputation rate per 1000 persons in
patients with diabetes from 11.2 in 1996 to 3.9 in 2008. Despite
this reduction, the rate of non-traumatic lowerextremity amputation
remains nearly eight-fold higher in patients with diabetes compared
with those without it.
Treatment of atherosclerosis
in diabetes
Advances in therapy have led to significant reductions in morbidity
and mortality for patients with diabetes (Table 1). The primary
focusof these treatments is the modification of risk factors forcardio-
vascular disease (Figure 4).
Hyperglycaemia
The potential role of glucose-lowering therapies in reducing cardio-
vascular events has been studied for more than two decades. Several
factors suggest that elevated glucose levels would be an important
therapeutic target. First, there is increased risk of cardiovascular
events with the very earliest signs of increased glucose levels, even
those below the threshold for a diagnosis of diabetes.67 Early work
with glucose-lowering therapies came tantalizingly close to demon-
strating a reduction in cardiovascular events. In the United
Kingdom Prospective Diabetes Study (UKPDS), there was a near
statistically significant reduction in myocardial infarction68,69 with
tight glucose control. The close results prompted several other
investigations to definitively answer the question. In The Action to
Control Cardiovascular Risk in Diabetes (ACCORD) Study, 10 251
patients (mean age, 62.2 years) with a median glycosylatedhaemoglo-
bin level of 8.1% were randomly assigned to intensive therapy [a
haemoglobin (Hgb) A1c ,6.0%] or standard therapy (a Hgb A1c
of 7.0–7.9%).70 Although there was a non-significant 10% trend in
the reduction of the primary endpoint (non-fatal myocardial infarc-
tion, non-fatal stroke, or death from cardiovascular causes), there
was a significant 22% increase in all-cause mortality in the intensively
treated group. A second large trial also failed to find any cardiovascu-
lar benefit to intensive control. In the Action in Diabetes and Vascular
Disease: Preterax and Diamicron Modified Release Controlled
Evaluation (ADVANCE) trial,71 11 140 patients with type 2 diabetes
were randomized to standard glucose control or intensive glucose
control (Hgb A1c ,6.5%). Intensive glucose control did not reduce
major macrovascular events, death from cardiovascular causes, or
death from any cause. A smaller, Veterans Affairs-based trial of more
poorly controlled subjects with type 2 diabetes also demonstrated
lack of efficacy with intensive control of hyperglycaemia.72 A
meta-analysis of 33 040 subjects from the five trials commonly asso-
ciated with ‘tight’ vs. ‘conventional’ control of glucose showed a 17%
reduction in myocardial infarction without improvement in stroke or
all-cause mortality rates.73 However, caution is required in the inter-
pretation of these data: the intensive treatment goal of UKPDS was
the same as the conventional goal of the more recent trials; the PRO-
spective pioglitAzone Clinical Trial In macroVascular Events (PRO-
active), also included in this meta-analysis, compared the addition of
a thiazolidinedione with placebo in patients with established athero-
sclerosis and was not specifically a study of more vs. less intensive
therapy74; and the ACCORD actually showed a mortality hazard. As
a result of these studies, the American Heart Association, American
College of Cardiology, and American Diabetes Association concluded
that a Hgb A1c goal of 7% should be maintained, and the decision to
pursue tighter control could be made on an individual basis.75
In contrast to the failure of targeting a glucose level, targeting the
mechanism of hyperglycaemia may yield better therapeutic out-
comes. Improving insulin sensitivity, rather than insulin levels, is a
strategy that has undergone study. The biguanide metformin has
demonstrated efficacy when compared with insulinotropic sulfony-
lureas. In UKPDS, among subjects with .120% of ideal body
weight, metformin was associated with a 42% reduction in diabetes-
related death and 36% reduction in all-cause mortality.68 The results
were difficult to interpret, for in the same study the addition of met-
formin to a sulfonylurea was associated with an increase in mortality.
In the 10-year follow-up of UKPDS, despite a lack of difference in gly-
cosylated haemoglobin between the metformin and sulfonylurea
arms in the 5 years after the initial study ended, metformin-treated
patients had a 33% reduction in myocardial infarction and 27% reduc-
tion in death from any cause, both significantly more than that in the
patients in the sulfonylurea arm.76 The value of metformin has been
supported in other studies as well. In the 19 691 diabetic patients with
in the Reduction of Atherothrombosis for Continued Health
(REACH) Registry, those treated with metformin had a 24% reduc-
tion in mortality compared with those not treated with metformin.77
In a nationwide Danish study, patients treated with an insulin secreta-
gogue, suffered a 19–32% increase in all-cause mortality compared
with those treated with metformin.78 The results were similar
whether or not the study subjects had a previous myocardial infarc-
tion. It is because of results like these that metformin is the recom-
mended first hypoglycaemic agent to be used in patients with type
2 diabetes.79 The thiazolidinediones, however, have a mixed
record of success in terms of cardiovascular outcomes. In the (PRO-
ACTIVE) trial, pioglitazone missed its primary cardiovascular end-
point (composite of all-cause mortality, non-fatal MI, stroke, acute
coronary syndrome, revascularization, and amputation) when
Figure 3 Incidence of ischaemic ulceration in a cohort of patient
with intermittent claudication. A total of 1244 men with claudica-
tion were followed for a mean of 45 months. Over the follow-up
period, men with diabetes were at a four-fold risk of ulceration
for every level of reduction in ankle perfusion pressure compared
with men without diabetes. DM, diabetes; ABI, ankle–brachial
index. Adapted from Aquino et al.59
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compared with placebo, but showed benefit in its composite second-
ary endpoint (all-cause mortality, non-fatal MI, and stroke),74 while
rosiglitazone has been associated with an increase in myocardial in-
farction but not all-cause mortality.80
Several other hypoglycaemic medications are commonly
employed for diabetes, but lack enough data to recommend their
use as treatments to reduce cardiovascular events. Acarbose, an
alpha glucosidase inhibitor, reduced the rate of myocardial infarction
by 91% and a composite of cardiovascular events (myocardial infarc-
tion, new angina, revascularization, cardiovascular death, congestive
heart failure, cerebrovascular events, and peripheral vascular
disease) by 49% in subjects with impaired glucose tolerance in the
STOP-Noninsulin Dependent Diabetes (NIDDM) trial.81 However,
cardiovascular risk reduction with acarbose has not been reported
in patients with diabetes. Neither incretin mimetics, dipeptidyl pep-
tidase (DPP)-4, nor sodium glucose co-transporter-2 (SGLT2) inhi-
bitors have any clinical trial data demonstrating cardiovascular
event reduction.
Ranolazine, a partial fatty acid oxidation inhibitor, improves func-
tional capacity in patients with stable angina and has been shown to
improve exercise tolerance similarly in patients with and without dia-
betes82 but does not reduce cardiovascular outcomes.27 As a partial
fatty acid oxidation inhibitor, it improves glucose utilization and has
consistently performed as a hypoglycaemic agent.82,83 Despite the
glucose-lowering capability, patients with diabetes do not gain
extra function or improved cardiovascular outcomes with ranola-
zine. Current guidelines do not support the use of these agents to
improve cardiovascular outcomes in patients with diabetes.79 More-
over, the safety requirements for the approval of hypoglycaemic
agents for type 2 diabetes has undergone scrutiny and now faces a
higher threshold at the Food and Drug Administration in the
United States.84
Hypertension
Treatment of hypertension was the first among the therapies of the
comorbidities of patients with diabetes to reduce mortality. In
UKPDS, 1148 hypertensive patients with diabetes were randomly
allocated to tight (more intensive) or standard blood pressure
control.85 Followed for 8.4 years, patients in the tight control arm
had a significantly lower blood pressure (144/82 mmHg) compared
with those in the standard control arm (154/87 mmHg) and had a
44% reduction in stroke and a 32% reduction in diabetes-related
death. The choice of first agent, beta-adrenergic blocker or
angiotensin-converting enzyme inhibitor, made no difference in the
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Table 1 Evidence for cardiovascular therapies in patients with diabetes mellitus
Condition supporting literature
Hyperglycaemia
In patients with diabetes
The use of metformin to lower Hgb A1c to ,7% in the prevention of cardiovascular disease events is
likely of value.
UKPDS76
The use of hypoglycaemic medications to achieve a target Hgb A1c of 6–6.5% to reduce cardiovascular
events is not beneficial and may be harmful when compared with a target of 7%.
ACCORD70 ADVANCE96
Hypertension
In patients with diabetes
Blood pressure should be reduced to ,140/90 mmHg in all risk settings. ALLHAT92
Patients with CHD, CVD, or PAD should receive an antagonist of the renin–angiotensin system. ALLHAT92 HOPE95 VALUE104
ONTARGET108
Blood pressure should not be routinely lowered to a target of ,120/80 mmHg. ACCORD-Blood Pressure91
Acceptable initial agents in the treatment of uncomplicated hypertension include beta-adrenergic blockers,
thiazide diuretics, and dihydropiridine calcium-channel blockers.
ALLHAT92
The use of alpha adrenergic blockers as initial therapy in uncomplicated hypertension is not recommended. ALLHAT92
Dyslipidaemia
In patients with diabetes
All patients, with or without a history of atherosclerotic vascular disease, should be treated with statins. HPS43 CARDS118
Routine administration of fibrates or long-acting niacin in addition to therapy with statins is not useful. ACCORD-Lipid129 AIM-HIGH131
The use of fibrates may be effective in selected patients who manifest an HDL ,34 mg/dL and triglycerides
.204 mg/dL.
SACKS130 FIELD127
Antiplatelet therapy
In patients with diabetes
The use of aspirin in the treatment of acute coronary syndromes and in the prevention of recurrent coronary
syndromes has been established.
ISIS-2141 AntiplateletTrialist’s
Collaboration137
The use of P2Y12 inhibitors in the treatment of acute coronary syndromes in addition to aspirin for the
prevention of recurrent coronary syndromes is established.
CURE145 TRITON28
P2Y12 inhibitors are superior to aspirin as monotherapy in patients with atherosclerotic vascular disease. CAPRIE142
The value of aspirin in the primary prevention of atherosclerotic vascular disease is unclear. JPAD138 POPADAD139
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outcomes, likely because the majority of patients required more than
one anti-hypertensive agent.85 Interestingly, the efficacy of treatment
of hypertension is not as durable as treatment of hyperglycaemiawith
metformin. Whereas the benefit of metformin in the first 5 years of
treatment persisted and increased over time,76 the benefit of tight
control of blood pressure did not persist once UKPDS had com-
pleted.86 The results suggest that the aggressive treatment of blood
pressure must be ongoing for the benefit to be maintained.
There is general agreement about the benefits of ‘optimal’ blood
pressure control, but not about the definition of ‘optimal’. Clinical
trials that were reported around the time of UKPDS provided
some clue as to the appropriate goal level. In the Hypertension
Optimal Treatment (HOT) trial, 18 790 patients with diastolic
blood pressure between 100 and 115 mmHg were randomly
assigned to treatment sufficient to achieve a diastolic blood pressure
of 90, 85 or 80 mmHg.87 In the patients with diabetes, there was a 51%
reduction in major cardiovascular events in the 80 mmHg target group
compared with the 90 mmHg target group. Similarly, in the Appropri-
ateBloodPressureControl inDiabetes (ABCD) trial, 470patientswith
diabetes were randomized to a target diastolic blood pressure of 80–
89 mmHgoradiastolicof75 mmHg.88 Althoughcardiovascularevents
did not differ between groups, all-cause mortality was lower in the
more aggressively treated group. Thus, in the Seventh Report of the
JointNationalCommittee (JNC)onPrevention, Detection, Evaluation,
and Treatment of High Blood Pressure,89 it was recommended that
patients with diabetes have their blood pressure controlled to 130/
80 mmHg or lower, although the report admitted that ‘available data
are somewhat sparse to justify the low target.’
The rationale of the Action to Control Cardiovascular Risk in Dia-
betes (ACCORD) trial was to determine with definitive clinical trial
evidence whether a more aggressive systolic blood pressure target of
,120 mmHg was superior to a systolic blood pressure target of
,140 mmHg.90 In ACCORD, 4733 patients were enrolled and the
goals were achieved: at 1 year, the intensive arm had a mean systolic
blood pressure of 119.3 mmHg and the standard group had a blood
pressure of 133.5 mmHg.91 After a mean follow-up of 5 years, there
was no significant difference in the primary outcome (non-fatal myo-
cardial infarction, non-fatal stroke, or death from cardiovascular
causes), death from any cause, or major coronary disease event.
However, there was a significant 40% reduction in stroke. Also, a sig-
nificant increase in medication-related adverse events was noted.
Subjects in the tight arm required 3.4 medications to achieve the
target compared with 2.1 medications in the standard group. We
await JNC 8 for any change in the recommended target of 130/
80 mmHg in patients with diabetes.
The preferred class of anti-hypertensive in patients with diabetes
merits consideration. The choice of agent may be predicated on
the presence of complications of diabetes. In the absence of compli-
cations, ALLHAT, the Antihypertensive and Lipid-Lowering Treat-
ment to Prevent Heart Attack Trial, demonstrated no difference in
Figure4 Comprehensive anti-atherosclerotic therapy in diabetes. The pathophysiology of diabetes-related atherogenesis is broad and requires a
comprehensive medical strategy to attenuate its progress. Improvements in dyslipidaemia, insulin resistance, hypertension, and platelet activation all
have a role in the care of patients with diabetes to minimize the complications of atherosclerosis. Statin therapy provides important risk reduction to
diabetic patients with and without diagnosed atherosclerosis. Improvement in glycaemia reduces the rate of myocardial infarction while metformin-
mediated improvements in insulin sensitivity provide long-term reductions in cardiovascular death. Antiplatelet therapy including aspirin and
thienopyridines have a definitive role in patients with atherosclerosis and a nuanced, individualized role in patients without a diagnosis of previous
myocardial infarction, stroke, or peripheral artery disease. Treatment of hypertension significantly reduces stroke and death. With the diagnosis of
atherosclerosis, antagonists of the renin–angiotensin system may play a heightened role.
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the primary outcome of fatal coronary heart disease or non-fatal
myocardial infarction among the chlorthalidone, amlodipine, and lisi-
nopril arms in patients with diabetes.92 Thus, if the primary goal of
treatment is the reduction of blood pressure, then a thiazide diuretic,
dihydropyridine calcium-channel blocker, or angiotensin-converting
enzyme inhibitor (ACE-I) are acceptable first choices. b-adrenergic
antagonists should not be considered as first-line agents for treating
hypertension in most patients. A meta-analysis of 12 studies evaluat-
ing 94 492 patients found that b-adrenergic blocker therapy was
associated with a 22% increased risk for new-onset diabetes, and a
15% increased risk of stroke compared with non-diuretic anti-
hypertensive agents.93 In contrast, b-adrenergic blocker therapy is
recommended for 3 years after myocardial infarction and in the
setting of left-ventricular dysfunction, with or without heart failure.
Moreover, b-adrenergic blocker therapy, titrated to full dose, is
recommended for the treatment of stable angina.94
If the goal is secondary prevention of atherosclerotic events,
antagonists of the renin–angiotensin system take precedence
because of the possible benefits beyond blood pressure lowering.
The efficacy of ACE-I therapy has been demonstrated in several
large clinical trials. In the Heart Outcomes Prevention Evaluation
(HOPE) study, 9297 subjects with atherosclerosis or diabetes and
a cardiovascular risk factor were randomly allocated ramipril or
placebo.95 The diabetic subgroup showed significant reductions in
MI, stroke, and death, despite a baseline blood pressure of 139/
79 mmHg prior to treatment. The ADVANCE trial enrolled 11 140
subjects with diabetes, irrespective of blood pressure, and randomly
allocated the subjects to perindopril and indapamide or matching
placebo.96 With a drop of 5.6 mmHg in systolic blood pressure, the
perindopril and indapamide combination reduced all vascular
events, but not cardiovascular events alone. In the EUropean trial
on Reduction Of cardiac events with Perindopril (EUROPA) trial of
patients with stable coronary artery disease, perindopril reduced
the composite endpoint of cardiovascular mortality, MI, or cardiac
arrest, similarly in those with and without diabetes.97 Interestingly,
when the 1502 diabetic subjects of EUROPA were evaluated inde-
pendently, no benefit could be demonstrated, likely suggesting inad-
equate power in this sized sample.98 In other trials of secondary
prevention after a cardiovascular event, ACE inhibition has been
shown to reduce recurrent stroke in diabetic patients with previous
stroke or TIA99 and reduce mortality in diabetic patients after myo-
cardial infarction.100 –102 Angiotensin receptor blockers (ARBs) have
similar efficacy toACE-I aftermyocardial infarction. In the Valsartan in
Acute Myocardial Infarction Trial,103 valsartan was as effective as cap-
topril for the primary endpoint of total mortality in the subgroup of
diabetic patients with myocardial infarction complicated by left-
ventricular systolic dysfunction.104 In the Losartan Intervention For
Endpoint reduction in hypertension study,105 losartan was found to
be superior to atenolol in diabetic patients with end-organ damage
for the primary composite endpoint of cardiovascular death, MI,
and stroke,106 and in the Valsartan Antihypertensive Long Term
Use Evaluation (VALUE), valsartan was equivalent to amlodipine
for the endpoint of cardiovascular morbidity and mortality in hyper-
tensive diabetic patients.107 The Ongoing Telmisartan Alone and in
Combination with Ramipril Global Endpoint Trial (ONTARGET)108
enrolled 25 620 patients with vascular disease or diabetes with
end-organ damage and randomized them to ramipril, telmisartan,
or the combination. After a median 56 months of follow-up, there
was no difference among the groups in the primary outcome of
death from cardiovascular cause, myocardial infarction, stroke, or
hospitalization for heart failure in the entire cohort and diabetic sub-
group.
Inhibitors of the mineralocorticoid receptor have been studied in
large trials in patientswith congestiveheart failure and left-ventricular
dysfunction after myocardial infarction. In the Randomized Aldac-
tone Evaluation Study (RALES) trial of patients with severe systolic
heart failure, spironolactone reduced mortality by 30% in patients
with and without diabetes.109,110 Two trials have evaluated the use
of eplerenone in patients with reduced left-ventricular systolic func-
tion, one in patients with mild heart failure and the other in patients
after myocardial infarction. In both trials, eplerenone reduced mor-
tality compared with placebo, and patients with diabetes received
the same benefit as those without diabetes.111,112
Recent trials, however, have cast doubt on the perceived superior-
ity of renin–angiotensin antagonists in patients with diabetes. In the
Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes
Research (NAVIGATOR) trial, 9306 subjects with impaired glucose
tolerance and established cardiovascular disease were randomized
to valsartan or placebo and followed for 5 years. Despite a 2.8/
1.4 mmHg difference in blood pressure between the groups, there
was no difference in death, myocardial infarction, stroke, and revas-
cularization.113 Similarly, in the Prevention Regimen for Effectively
Avoiding Second Strokes (PRoFESS) trial, telmisartan failed to
reduce stroke and major cardiovascular events in diabetic patients
with recent stroke when compared with placebo.114 In contrast,
the ACCOMPLISH trial in which 60% of patients had diabetes
showed that treatment with the ACE-I benzapril in combination
with amlodipine significantly reduced cardiovascular events.115 For
now, the usefulness of ACE-I and ARB in diabetic patients with myo-
cardial infarction remains clear, but the preferential role in other set-
tings less so.
Dyslipidaemia
The cornerstone of lipid management in diabetes is the
hydroxymethylglutaryl-CoA reductase inhibitors (statins). The land-
mark Heart ProtectionStudyestablished the role of statins in the treat-
ment of patients with diabetes.116 In the 5963 subjects with diabetes
and no cardiovascular disease, there were significant reductions in
first non-fatal myocardial infarction or death, major coronary events,
stroke, and revascularization in the group treated with simvastatin
compared with the group treated with placebo. These benefits were
recapitulated with atorvastatin in Anglo-Scandinavian Cardiac Out-
comes Trial—lipid-lowering arm117 and the Collaborative Atorvasta-
tin Diabetes Study.118 Statins have an even more profound effect in
diabetic subjects preventing recurrent myocardial infarction and a
similar benefit in preventing stroke compared with patients without
diabetes.119–121 Thus, patients with diabetes should be treated with
a statin. The one exception may be in patients with renal failure, as
statins have failed to show efficacy consistently is in diabetic patients
undergoing haemodialysis.122,123 Moreover, high-dose more potent
statins have been shown to be superior to a lower dose of the same
medication or less-potent statins in two clinical trials, indicating that
a high dose of a more potent statin therapy should be used in standard
practice.124,125
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The usefulness of other lipid modification agents, alone or in add-
ition to statins, in patients with diabetes is not established. Early work
with fibric acid derivatives alone demonstrated a similar reduction in
cardiovascular events in patients with and without diabetes in the
Veterans Affairs High-Density Lipoprotein Cholesterol Intervention
Trial,126 but more recent data have been less compelling. The Feno-
fibrate Intervention and Event Lowering in Diabetes (FIELD) trial ran-
domized 9795 patients with type 2 diabetes to fenofibrate or
placebo,127 but was unable to show a reduction in the primary
outcome of coronary events. The lack of efficacy was posited to an
unequal distribution of statin usage. The use of fenofibrate was asso-
ciated with a reduction in minor amputation,128 although interpret-
ation of a secondary endpoint without a positive primary endpoint
should be done with caution. The use of a fibrate in supplement to
statin therapy for all subjects with diabetes was studied in the
ACCORD Lipid trial.129 In this trial of 5518 patients, all patients
received open label simvastatin and were randomized to fenofibrate
or placebo. After a mean follow-up of nearly 5 years, despite signifi-
cantly lower triglyceride and higher high-density lipoprotein (HDL)
levels in the fenofibrate arm, there was no difference in the rate of
major fatal or non-fatal cardiovascular events, stroke, or death.
Based on this trial, routine use of a fibrate in addition to statin
therapy is not warranted. Some have suggested that fibrates may
have value in patients with high triglyceride and low HDL levels,130
but this remains to be proved prospectively. Similarly, niacin has yet
to find a treatment niche when statins are in use. In the Atherothrom-
bosis Intervention in Metabolic Syndrome with Low HDL/High Tri-
glycerides: Impact on Global Health Outcomes (AIM-HIGH) trial,
3414 patients with established vascular disease on a statin with low
HDL and high triglycerides were randomized to extended release
niacin or placebo.131 Niacin treatment significantly increased HDL,
lowered triglyceride, and lowered LDL levels, but therewas no differ-
ence in the composite of death from coronary heart disease, non-
fatal myocardial infarction, ischaemic stroke, hospitalization for an
acute coronary syndrome, or symptom-driven coronary or cerebral
revascularization or any of the individual components in the entire
cohort and diabetic subgroup. For now, the addition of a second
lipid modifying medication may be made on an individual basis, but
cannot be recommended for all patients with diabetes.
Antiplatelet therapy
The benefit of antiplatelet therapy in patients with diabetes but
without evident atherosclerosis has become less clear with time.
The current recommendation by the US Preventive Services Task
Force and the American College of Chest Physicians is low-dose
aspirin for primary prevention in all patients.132,133 This recommen-
dation is largely based on meta-analyses of many primary prevention
trials showing a small benefit of aspirin in the reduction of non-fatal
myocardial infarction (about five events per 10 000 patients) offset
by a similar increase in gastrointestinal hemorrhage (three events
per 10 000 patients).134– 137 However, the data in diabetic patients
in particular is not compelling. Two recent trials enrolled only
patients with diabetes and found no benefit. The Japanese Primary
Prevention of Atherosclerosis with Aspirin for Diabetes (JAPAD)
Trial included 2539 patients with diabetes and no history of athero-
sclerotic disease.138 There was a non-significant 20% reduction in
atherosclerotic events (fatal and non-fatal MI, fatal and non-fatal
stroke, and peripheral artery disease). Similarly, in the Prevention
of Progression of Arterial Disease and Diabetes (POPADAD) trial,
1276 adults with type 2 diabetes and an ankle–brachial index of
,1.0 were randomized to daily aspirin or placebo.139 In this study,
there was no significant difference in the composite outcome of
death from coronary heart disease or stroke, non-fatal myocardial in-
farction or stroke, or above ankle amputation for critical limb ischae-
mia; or any of its individual components. A meta-analysis of aspirin
treatment in only the diabetic subjects in large primary prevention
studies demonstrated a trend towards a 10% reduction in the cardio-
vascular disease events.140 Based on the limited data and small, if any
benefit, the American Diabetes Association, American Heart Associ-
ation, and American College of Cardiology Foundation recommend
the use of low-dose aspirin in diabetic patients with a cardiovascular
disease riskof.1% per year based on diabetes-based risk calculators
like the UKPDS Risk Engine (http://www.dtu.ox.ac.uk/riskengine/
index.php) or American Diabetes Association Risk Assessment
Tool (http://www.diabetes.org/phd).140 Thus, diabetes alone is not
enough to warrant low-dose aspirin therapy, but use of aspirin may
be acceptable when the cardiovascular risk surmounts the 1% per
year needed to gain the small benefit of aspirin in primary prevention.
In patients with acute coronary syndromes aspirin significantly
reduced the rate of reinfarction, stroke, and death.141 More potent
than aspirin, the P2Y12 inhibitors, have been studied in secondary
prevention, both in the acute phase of coronary syndromes and
stroke and during stable chronic follow-up. In the Clopidogrel vs.
Aspirin in Patients at Risk of Ischemic Events (CAPRIE) trial, 19 185
patients with coronary artery disease, cerebrovascular disease, or
peripheral artery disease were randomized to aspirin or clopido-
grel.142 A modest 0.5% absolute annual risk reduction was noted.
In the diabetic subgroup of 1952 patients, the absolute risk reduction
was 2.1%, significantly larger than in subjects without diabetes.143
However, in The Clopidogrel for High Atherothrombotic Risk and
Ischemic Stabilization, Management, and Avoidance (CHARISMA)
trial of patients with established atherosclerosis or multiple risk
factors for atherosclerosis, the addition of clopidogrel to aspirin
was no more effective than aspirin alone in the prevention of the
composite endpoint of cardiovascular death, MI, and stroke.144 Fol-
lowing acute coronary syndromes, there is evidence that greater anti-
platelet inhibition provides more benefit for patients with diabetes.
The Clopidogrel in Unstable Angina to Prevent Recurrent Events
(CURE) trial demonstrated benefit in reducing the composite of car-
diovascular death, non-fatal MI, and stroke with the addition of clopi-
dogrel to aspirin in both non-diabetic and diabetic patients with acute
coronary syndrome.145 In TRITON-TIMI 38 trial, patients with acute
coronary syndromes undergoing percutaneous revascularization
were randomly allocated to clopidogrel or prasugrel. The benefit
associated with the more potent prasugrel was significantly greater
for subjects with diabetes than those without diabetes, despite no
excess bleeding.28 In the Targeted Platelet Inhibition to Clarify the
Optimal Strategy to Medically Manage Acute Coronary Syndromes
(TRILOGY ACS) trial, patients randomized to prasugrel had a
lower rate of recurrent events than those randomized to clopidogrel.
In contrast to TRITON-TIMI 38, the patients with diabetes did not
have a better result than those without diabetes.146 Another novel
P2Y12 inhibitor, ticagrelor, was tested in patients with acute coron-
ary syndromes and compared with clopidogrel in the Platelet
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Inhibition and Patient Outcomes (PLATO) trial. In Plato, ticagrelor
was superior to clopidogrel and showed a significant reduction in
mortality, but the benefit for subjects with diabetes was not different
from the cohort as a whole.147,148 Further work is needed to clarify
these differences among agents and their interaction with diabetes.
The benefit of risk modification in
aggregate
Modifications of each of the risk factors brings reductions in cardio-
vascular adverse events. Intensive modification of every risk factor
provides additive benefits. In the Steno-2 trial, 160 patients with
type 2 diabetes were randomized to intensive therapyorconvention-
al therapy and followed for up to 13 years.149 Intensive therapy was
defined as haemoglobin A1c ,6.5%, total cholesterol ,175 mg/
dL, fasting serum triglycerides ,150 mg/dL, systolic blood pressure
,130 mmHg, diastolic blood pressure,80 mmHg, use of low-dose
aspirin, and treatment with renin–angiotensin antagonist. Intensive
therapy significantly reduces cardiovascular and total mortality com-
pared with standard treatment. Thus, intensive therapy of all the risk
factors for atherosclerosis is life extending and should be pursued.
Indeed, intensive medical therapy is so effective, that investigation
for coronary artery disease in asymptomatic patients is unnecessary.
In the Detection of Ischemia in Asymptomatic Diabetics (DIAD)
study, 1123 subjects with type 2 diabetes were randomly assigned
to adenosine stress radionuclide myocardial perfusion imaging or
no screening.150 Over nearly 5 years of follow-up, there was a cumu-
lative cardiac death or non-fatal myocardial infarction rate of 2.9%,
without difference between the two groups. Thus, aggressive use
of risk modifying therapies remains the mainstay of therapy. On the
other hand, intensive treatment of risk factors, namely hypertension
and hyperglycaemia may also associate with increased cardiovascular
events in the diabetic population.70,151 Hence, a cautious approach
should be implemented when considering individual therapeutic
targets in this setting.
Coronary revascularization
The role of revascularization in diabetes has evolved over the recent
years. The Clinical Outcomes Utilizing Revascularization and Aggres-
sive Drug Evaluation (COURAGE) trial included 2287 patients with
significant stable coronary artery disease and compared the out-
comes of optimal medical therapy (OMT) with and without percu-
taneous coronary intervention (PCI).152 Over a median 4.6 years of
follow-up, the addition of PCI to OMT did not reduce death and
MI compared with OMT alone, either in the entire cohort or the sub-
group with diabetes. Thus, in most patients with stable coronary
artery disease, who have preserved left-ventricular function and
have not exhibited severe myocardial ischaemia on a stress test,
may be treated with optimal medical therapy alone for the reduction
in death and MI, unless an acute coronary syndrome develops. The
use of PCI for symptom reduction was superior in COURAGE and
may be applied on an individual basis, should medical therapy fail.
The Bypass Angioplasty Revascularization Investigation 2 Diabetes
(BARI 2D) trial provided similar results. In this trial, 2368 patients
with type 2 diabetes and heart disease were given intensive medical
therapy and randomized to prompt revascularization or expected
management.153 In the revascularization arm, the responsible
physician determined the appropriate strategy. Over the course of
5 years of follow-up, there was no difference in survival between
the medical therapy and revascularization arms in total, or by type.
In a secondary outcome, the patients in the coronary artery bypass
portion of the study who underwent surgery had a significantly
lower rate of major cardiovascular events (death, MI, or stroke)
than those allocated to medical therapy. This may have resulted
because the patients in the bypass arm had more triple vessel coron-
ary artery disease (52.4 vs. 20.3%). The Future Revascularization
Evaluation in Patients with Diabetes Mellitus: Optimal Management
of Multivessel Disease (FREEDOM) trial compared the outcomes
in 1900 diabetic subjects with multivessel coronary disease randomly
assigned to percutaneous coronary intervention or coronary artery
bypass grafting and followed for a median of 3.8 years.154 Subjects
who underwent surgical bypass had an absolute 7.9% reduction in
the primary outcome of death, non-fatal myocardial infarction, and
non-fatal stroke. Indeed, the reduction in death from any cause was
significant by itself, with a 5.4% absolute reduction in all-cause mor-
tality. Thus, in patients with diabetes and multivessel disease who
require revascularization, coronary artery bypass surgery is pre-
ferred over percutaneous coronary intervention.
Conclusion
Diabetes is a risk multiplier in atherosclerosis. It increases the risk of
developing atherosclerosis, the incidence of complications of athero-
sclerosis, and is associated with poorer outcomes from these events.
Health care professionals now have the benefit of a wide variety of
clinical trial data supporting specific treatments and targets for
patients with diabetes. These include lipid-lowering therapy with
statins, blood pressure control, and antiplatelet therapy in patients
with increased cardiovascular risk scores. Hyperglycaemia should
be treated to a target glycosylated haemoglobin of 7%, with
therapy that includes an agent that improves insulin sensitivity, such
as metformin. Optimal medical treatment, including risk factor modi-
fication, antiplatelet therapy, and antianginal medications is the pre-
ferred approach for most patients with diabetes and stable
coronary artery disease. Over the last decade, aggressive application
of these therapies by care providers has reduced the rate of cardio-
vascular events in patients with diabetes, ameliorating outcomes in
this population. Despite these improvements, the risk of adverse car-
diovascular outcomes remains significantly higher in patients with
diabetes than thosewithout diabetes. Understanding the pathophysi-
ology of vascular disease in diabetes, as reviewed in Part I of this
review will facilitate discovery of beneficial treatments for diabetic
patients to reduce this gap in morbidity and mortality.
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